Department of Psychiatry and Addictology, APHP, Paul Brousse Hospital, Villejuif, France.
Faculte de Medecine, Paris Sud University, Le Kremlin-Bicetre, Île-de-France, France.
J Psychopharmacol. 2020 Oct;34(10):1079-1085. doi: 10.1177/0269881120919957. Epub 2020 May 25.
Psychedelic drugs have shown an efficacy in some psychiatric disorders and have an original mechanism of action with a 5-HT agonism.
The aim of this meta-analysis was to assess by a quantitative analysis the putative efficacy of psychedelic drugs on depressive symptoms and to investigate the kinetic of this efficacy.
We searched the MEDLINE and PsycINFO databases through April 2019, without limits on year of publication. Means and standard deviations were extracted to calculate standardized mean differences (SMD). Scores of depressive symptoms were compared with baseline scores at days 7, 14, and 21; weeks 4-5 and 6-8; and months 3 and 6.
Eight studies were included in this meta-analysis. A significant decrease of depressive symptoms was found from day 1 ( = 5 studies; SMD = ‒1.4, 95% confidence interval (CI): ‒2.33 to ‒0.48, = 0.003) to 6 months ( = 4 studies; SMD = ‒1.07, 95% CI: ‒1.44 to ‒0.7, < 0.001) after psychedelic sessions. No serious adverse effect was reported in all included studies. A transient increase of the heart rate, blood systolic, and diastolic pressure were found after psychedelics compared with placebo.
This meta-analysis shows that psychedelic treatments were safe and could contribute to a rapid improvement of depressive symptoms.
迷幻药物在一些精神疾病中显示出疗效，并且具有 5-HT 激动剂的原始作用机制。
本荟萃分析的目的是通过定量分析评估迷幻药物治疗抑郁症状的潜在疗效，并研究这种疗效的动力学。
我们通过 MEDLINE 和 PsycINFO 数据库进行了搜索，截止日期为 2019 年 4 月，没有发布年份的限制。提取均值和标准差以计算标准化均数差值（SMD）。抑郁症状评分与第 7、14 和 21 天，第 4-5 周和第 6-8 周，第 3 和第 6 个月的基线评分进行比较。
本荟萃分析纳入了 8 项研究。从第 1 天（ = 5 项研究；SMD = ‒1.4，95%置信区间（CI）：‒2.33 至 ‒0.48， = 0.003）到 6 个月（ = 4 项研究；SMD = ‒1.07，95% CI：‒1.44 至 ‒0.7， < 0.001），迷幻药物治疗后，抑郁症状显著减轻。所有纳入的研究均未报告严重不良事件。与安慰剂相比，迷幻药物治疗后发现心率、收缩压和舒张压短暂升高。
本荟萃分析表明，迷幻药物治疗是安全的，可以快速改善抑郁症状。
